HOME / Notice / News / EN
NKCL BioGroup, a biotechnology company specializing in NK (Natural Killer) cell therapeutics and Automated Culture Systems (ACS), announced on the 3rd that it has signed an exclusive business cooperation agreement with its Mongolian local partner TYBO to introduce cell therapy business into Mongolia....
[2026 Consumer Recommendation No.1 Brand] NKCL Bio NKCL Bio Group (NKCL Bio) has won the Grand Prize in the Advanced Regenerative Medicine category at the 2026 Consumer Recommendation No.1 Brand Awards hosted by the Chosun Ilbo. Recently, the advanced regenerative medicine market has been shifting be...
Dangnyangiwa Saramdeul to Build Pet Immunity-Based Healthcare Business Model with NKCL Bio Group, a Specialized NK Cell Therapy Company Pet life-care platform company Dangnyangiwa Saramdeul announced on the 18th that it has signed a memorandum of understanding (MOU) with immune cell-based biotechnolo...
Expansion of NK cell-based immunotherapy into pet healthcare… advancing a data-driven precision healthcare model NKCL Bio Group Co., Ltd. (CEO: Donghwa Shin), a biotechnology company specializing in immune cell-based technologies, has officially entered the companion animal immune healthcare market....
Linkage between clinical research and manufacturing process begins in earnest… Promote standardization of the entire cell therapy development cycle Han Family Nursing Hospital and NKCL Bio Group have begun building an integrated platform encompassing advanced regenerative medicine clinical research ...
